A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer ...

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...